Tag: securities exchange

Dubai and New York, June 2, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), today announces the successful closing of a USD 1.4 billion dual-tranche senior unsecured notes offering (the “Offering”) by its subsidiary VEON Midco B.V. (the “Issuer”). The Offering refinances substantially all of VEON’s debt maturing in 2027 ahead of schedule and reflects sustained confidence in VEON’s digital operator transformation and AI1440 strategy.

LONDON, June 02, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, is pleased to provide investors with further insight into the progression of its AI-powered agentic infrastructure across both investor and consumer-facing operations following completion of its recently announced Australian wellness platform transaction.

Combined platform unifies multimodal AI-powered physical threat detection with patented emergency response technology, creating real-time situational intelligence across K-12 schools, and senior living.

WINTER PARK, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”), an owner and operator of high-quality open-air retail centers located primarily in high-growth markets across the Southeast and Southwest, announced today the sale of Madison Yards, a 163,000-square-foot grocery-anchored shopping center in Atlanta, Georgia (the “Property”) for $73.3 million, representing a price of $451 per square foot.

HOUSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) filed its definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission (the “SEC”) on April 21, 2026, in connection with Weatherford’s proposal to Redomesticate from Ireland to the United States of America (the “U.S.”). Capitalized terms used herein but not defined have the meanings set forth in the Proxy Statement.

Targeted to Begin Generating Revenue Between Late 2028 and Mid-2029 Following Siemens Restoration at U.S. Facilities.

Hong Kong, June 01, 2026 (GLOBE NEWSWIRE) -- JM Group Limited (NYSE American: JMG) (the “Company” or “JMG”), a Hong Kong-headquartered sourcing and wholesale solutions provider for a wide array of consumer products, today provided the following further updates regarding the Company’s response to the trading halt placed by the New York Stock Exchange (“NYSE”) and the relevant regulatory inquiries previously announced by the Company on February 2, 2026.

WEST PALM BEACH, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- LXP Industrial Trust (“LXP”) (NYSE:LXP), a real estate investment trust focused on Class A warehouse and distribution real estate investments, today provided a recent business activity update and increased its 2026 Adjusted Company FFO guidance range ahead of its participation in REITweek, NAREIT’s upcoming 2026 Investor Conference.

Line-fit integration of the Viasat Hybrid SATCOM Approach for the C-130J presents opportunity to expand high-capacity, resilient connectivity across multi-mission airlift operations

Seasoned international finance leader to support Kyivstar’s continued growth and digital transformation

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) and certain officers. The class action, filed in the United States District Court for the District of Connecticut, and docketed under 25-cv-01120, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Biohaven securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 sand Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.